Sight Sciences announced positive findings from a recently published meta-analysis evaluating the clinical and economic impact of its Omni Surgical System. Published in the European Journal of Ophthalmology and presented at the European Society of Cataract & Refractive Surgeons (ESCRS) meeting in Copenhagen, Denmark, the analysis reviewed data from 22 unique studies involving 2,379 eyes. It confirmed the Omni system’s effectiveness and safety in treating open-angle glaucoma (OAG), both as a standalone procedure and when combined with cataract surgery.

According to the data, Omni achieved a 20% or greater reduction in intraocular pressure (IOP) in nearly 89% of patients over 6, 12, and 24 months. IOP levels dropped significantly and remained stable over time. Mean IOP reduction was 6.4 to 10.0 mmHg at 12 months for patients with a baseline IOP ≥18 mmHg. For patients with a baseline IOP <18 mmHg, mean IOP reduction was 1.3 mmHg at 12 months. Other key findings include:

• Approximately two-thirds of patients remained medication-free up to one year after surgery.

• Average IOP-lowering medication use decreased from of 0.9 to 3.4 medications at baseline to 0.1 to 2.2 medications at month 12 (standalone and combination).

• Adverse events were generally mild and transitory.

• Patients treated with Omni also showed slightly better quality-adjusted life years.

OMNI is designed for implant-free, minimally invasive glaucoma surgery (MIGS) and targets all 3 points of resistance in the eye’s natural fluid drainage system, according to Sight Sciences. GP